Using whole disease modeling to inform resource allocation decisions: Economic evaluation of a clinical guideline for colorectal cancer using a single model

Value in Health

Volumn 16, Issue 4, 2013, Pages 542-553

  Tappenden, Paul ^a   Chilcott, Jim ^a   Brennan, Alan ^a   Squires, Hazel ^a   Glynne Jones, Rob ^b   Tappenden, Janine ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

^c Doncaster and Bassetlaw Hospitals NHS Foundation Trust   (United Kingdom)

Author keywords

colorectal cancer; economic analysis; simulation models

Indexed keywords

CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; BARIUM ENEMA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DISEASE MODEL; FOLLOW UP; HUMAN; HYPOTHESIS; INVESTMENT; LIVER METASTASIS; MEDICAL AUDIT; META ANALYSIS (TOPIC); METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; MICROSURGERY; MONTE CARLO METHOD; MULTIMODALITY CANCER THERAPY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RADICAL RESECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESOURCE ALLOCATION; SIGMOIDOSCOPY; SIMULATION; TRANSANAL ENDOSCOPIC MICROSURGERY;

BAYES THEOREM; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION MAKING; FEASIBILITY STUDIES; HEALTH CARE RATIONING; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; MONTE CARLO METHOD; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84879416308     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.02.012     Document Type: Article

References (62)

1. Tappenden P, Chilcott J, Brennan A, Squires H, Stevenson M. Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework. Value Health 2012;15:1127-36.
2. A. Wailoo, J. Roberts, J. Brazier, and C. McCabe Efficiency, equity and NICE clinical guidelines BMJ 328 2004 536 537
3. National Institute for Health and Clinical Excellence The Guidelines Manual 2009 National Institute for Health and Clinical Excellence London
4. National Institute for Health and Clinical Excellence Clinical Guideline - The Diagnosis and Management of Colorectal Cancer 2011 National Institute for Health and Clinical Excellence London
5. Tappenden P. Conceptual modelling for health economic model development. Health Economics and Decision Science Discussion Paper Series 12/05. 2012. Available from: http://www.shef.ac.uk/scharr/sections/heds/. [Accessed January 6, 2012].
6. Tappenden P, Glynne-Jones, Shorthouse A, et al. Colorectal cancer and its detection, diagnosis, treatment and follow-up: disease and treatment pathways. Health Economics and Decision Science Discussion Paper Series 12/09. Available from: http://www.shef.ac.uk/scharr/sections/heds/. [Accessed January 6, 2012].
7. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Clinical Excellence, 2008.
8. W.S. Atkin, and B.P. Saunders Surveillance guidelines after removal of colorectal adenomatous polyps Gut 51 Suppl. 5 2002 v6 v9
9. R.B. Turnbull, K. Kyle, F.R. Watson, and J. Spratt Cancer of the colon: the influence of the no touch isolation technic on survival rates Ann Surg 166 1967 421 425
10. C.E. Dukes The classification of cancer of the rectum J Pathol Bacteriol 35 1932 323-2
11. National Institute for Health and Clinical Excellence Cetuximab for the First-Line Treatment of Metastatic Colorectal Cancer. Technology Appraisal No. 176 2009 National Institute for Health and Clinical Excellence London
12. P. Trueman, J.B. Chilcott, and K. Lowson Bowel Cancer Services: Costs and Benefits. Report to the Department of Health 2010 York: York Health Economics Consortium/University of Sheffield
13. D. Weller, S. Moss, and P. Butler English Pilot of Bowel Cancer Screening: An Evaluation of the Second Round. Report to the Department of Health 2006 The Institute of Cancer Research Edinburgh
14. Office for National Statistics. Registrations of cancer diagnosed in 2007. Series MB1 No. 38, 1-44. Available from: http://www.statistics.gov.uk/ downloads. [Accessed May 4, 2010].
15. J.R. Dunne, C. Gannon, and T.M. Osborn Perioperative anemia in colon cancer: assessment of risk factors Am Surg 68 2002 582 587
16. P. Finan, J. Smith, and E. Morris National Bowel Cancer Audit 2009 2011 Association of Coloproctology of Great Britain and Ireland Leeds
17. P.P. Tekkis, R. Kinsman, and M.R. Thompson The Association of Coloproctology of Great Britain and Ireland study of large bowel obstruction caused by colorectal cancer Ann Surg 240 2004 76 81
18. A.R. Williams Polyps and cancer of the large bowel: a necropsy study in Liverpool Gut 23 1982 835 842
19. S. Whyte, C. Walsh, and J.B. Chilcott Bayesian calibration of a natural history model with application to a population model for colorectal cancer Med Decis Making 31 2011 625 641
20. J.E. Allison, I.S. Tekawa, L.J. Ransom, and A.L. Adrain A comparison of fecal occult-blood tests for colorectal-cancer screening N Engl J Med 334 1996 155 160
21. J.E. Allison, R. Feldman, and I.S. Tekawa Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value Ann Intern Med 112 1990 328 333
22. I.M. De Zwart, G. Griffioen, and M.P. Shaw Barium enema and colonoscopy for the detection of colorectal neoplasia: sensitivity, specificity, complications and its determinants Clin Radiol 56 2001 401 409
23. D.K. Rex, E.Y. Rahmani, and J.H. Haseman Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice Gastroenterology 112 1997 17 23
24. S. Halligan, D.G. Altman, and S.A. Taylor CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting Radiology 237 2005 893 904
25. A. Graser, P. Stieber, and D. Nagel Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population Gut 58 2009 241 248
26. A. Blakeborough, M.B. Sheridan, and A.H. Chapman Complications of barium enema examinations: a survey of UK consultant radiologists 1992 to 1994 Clin Radiol 52 1997 142 148
27. C.J.A. Bowles, R. Leicester, and C. Romaya A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow? Gut 53 2004 277 283
28. D. Burling, S. Halligan, and A. Slater Potentially serious adverse events at CT colonography in symptomatic patients: National Survey of the United Kingdom Radiology 239 2006 464 471
29. UK Flexible Sigmoidoscopy Screening Trial Investigators Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial Lancet 359 2002 1291 1300
30. N.M. Gatto, H. Frucht, and V. Sundararajan Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study J Natl Cancer Inst 93 2010 230 236
31. D. Sebag-Montefiore, R.J. Stephens, and R. Steele Preoperative radiotherapy versus selective postoperative chemoradiation in patients with rectal cancer (MRC CR07 and NCIC-CTG-C016): a multicentre, randomised trial Lancet 373 2009 811 820
32. Clinical Outcomes of Surgical Therapy Study Group A comparison of laparoscopically assisted and open colectomy for colon cancer N Engl J Med 350 2004 2050 2059
33. T. Andre, C. Boni, and L. Mounedji-Boudiaf Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343 2351
34. *Phys 63 2005 745 752
35. H.C. Bucher, G.H. Guyatt, and L.E. Griffith The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 1997 683 691
36. V. Golfinopoulos, G. Salanti, and N. Pavlidis Survival and disease progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis Lancet Oncol 8 2007 898 911
37. M. Seymour, T.S. Maughan, and J.A. Ledermann Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 2007 143 152
38. R. Adam, V. Delvart, and A. Valeanu Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival Ann Surg 240 2004 644 657
39. C. Tournigand, T. André, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237
40. F.H. Shabaruddin, R.A. Elliott, and J.W. Valle Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom Br J Cancer 103 2010 315 323
41. K. Cooper, H. Pilgrim, and C. Carroll Chemoprevention of colorectal cancer: a systematic review and economic model Health Technol Assess 14 2010 i-203
42. P. Kind, G. Hardman, and S. Macran UK Population Norms for EQ-5D. Centre for Health Economics Discussion Paper No 172 1999 University of York York 1-98
43. S.D. Ramsey, M.R. Anderson, and R. Etzioni Quality of life in survivors of colorectal carcinoma Cancer 88 2000 1294 1303
44. S. Petrou, and N. Campbell Stabilisation in colorectal cancer Int J Palliat Nurs 3 1997 275 280
45. Department of Health. NHS Reference Costs 2010-11. Available from: http://www.dh.gov.uk/health/category/publications/reports-publications/. [Accessed April 5, 2012].
46. Joint Formulary Committee British National Formulary 61 2012 B.M.J. Group and Pharmaceutical Press London
47. L. Curtis Unit Costs of Health and Social Care 2011 Personal Social Services Research Unit Kent
48. A. Boland, A. Haycox, A. Bagust, and L. Fitzsimmons A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses Health Technol Assess 7 2003 i-112
49. E. Remák, and L. Brazil Cost of managing women presenting with stage IV breast cancer in the United Kingdom Br J Cancer 91 2004 77 83
50. H.S. Osman, H.I. Rashid, N. Sathananthan, and M.C. Parker The cost effectiveness of self-expanding metal stents in the management of malignant left-sided large bowel obstruction Colorectal Dis 2 2000 233 237
51. P. Tappenden, J.B. Chilcott, and S. Eggington Option appraisal of population-based colorectal cancer screening programmes in England Gut 56 2007 677 684
52. S. Maslekar, S.H. Pillinger, and A. Sharma Cost analysis of transanal endoscopic microsurgery for rectal tumours Colorectal Dis 9 2007 229 234
53. J.F. Bosset, L. Collette, and G. Calais Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123
54. S. Mocellin, S. Pasquali, and D. Nitti Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer Cochrane Database Syst Rev 2009 3
55. I. Durand-Zaleski, S. Earlam, and C. Fordy Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases Cancer 83 1998 882 888
56. V. Golfinopoulos, G. Salanti, N. Pavlidis, and JPA Ioannidis Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis Lancet Oncol 8 2007 898 911
57. P. Tappenden, R. Jones, S. Paisley, and C. Carroll Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer Health Technol Assess 11 2007 i-128
58. M. Jeffery, B.E. Hickey, and P.N. Hilder Follow-up strategies for patients treated for non-metastatic colorectal cancer Cochrane Database Syst Rev 4 2008 i-35
59. M. Johannesson, and M.C. Weinstein On the decision rules of cost-effectiveness analysis J Health Econ 12 1993 459 467
60. S. Birch, and A. Gafni Cost-effectiveness/cost-utility analyses: do current decision rules lead us where we want to be? J Health Econ 11 1992 279 296
61. M.C. Weinstein, P.G. Coxson, and L.W. Williams Forecasting coronary heart disease incidence, mortality and cost: the Coronary Heart Disease Policy Model Am J Public Health 77 1987 1417 1426
62. D.M. Eddy, and L. Schlesinger Archimedes: a trial validation model of diabetes Diabetes Care 26 2003 3093 3101